Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study.

[1]  L. Kiemeney,et al.  Long-Term Risk Of Re-Treatment Of Patients Using α-Blockers For Lower Urinary Tract Symptoms , 2002 .

[2]  M. Marberger,et al.  Prostate Volume and Serum Prostate–Specific Antigen as Predictors of Acute Urinary Retention , 2000, European Urology.

[3]  M. Michel,et al.  Treatment Satisfaction of Patients with Lower Urinary Tract Symptoms: Randomised Controlled Trials vs. Real Life Practice , 2000, European Urology.

[4]  D. Comet,et al.  One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire , 2000 .

[5]  C. Roehrborn,et al.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. , 1999, Urology.

[6]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[7]  R. Roberts,et al.  Natural history of prostatism: risk factors for acute urinary retention. , 1997, The Journal of urology.

[8]  H. Lepor,et al.  Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. , 1997, The Journal of urology.

[9]  A L Gould,et al.  Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. , 1996, Urology.

[10]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[11]  H. Lepor.  Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia* , 1995 .

[12]  H. Lepor,et al.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. , 1992, The Journal of urology.

[13]  G. Andriole,et al.  The effect of finasteride in men with benign prostatic hyperplasia. , 1992, The Journal of urology.

[14]  R. Roberts,et al.  Longitudinal changes in peak urinary flow rates in a community based cohort. , 2000, The Journal of urology.